REFERENCES

[1]   Jackson J, Prince M. World Alzheimer Report 2009: Executive Summary. Alzheimer's Disease International 2009;1-21.

[2]   Kidd PM. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern Med Rev 2008;13:85-115.

[3]   Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol 2006;545:39-50.

[4]   Fredman L, James BD, Johnson TJ, Scholz KP, Weuve J. 2012 Alzheimer's disease facts and figures. Alzheimer's Association 2012;8:1-72.

[5]   Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer's disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22.

[6]   Maslow K. Early-Onset Dementia: A National Challenge, A Future Crisis. Alzheimer's Association 2006;1:1-68.

[7]   Miniño AM, Xu J, Kochanek K. Deaths: Final Data for 2008. National Vital Statistics Reports. National Center for Health Statistics 2011;59:1-126.

[8]   Miniño AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: Final Data for 2000: National Vital Statistics Reports. National Center for Health Statistics 2002;50:1-120.

[9]   Kairid A, Chunsirikarn S. Prevalence Reported of Alzheimer's Disease in Thailand: 2005-2007. Health Information System Development office (Hiso) in Thailand 2007.

[10] Kongklidekun S, Bunhansupawat T, Kamsiri A, Sukprasong P, Chatthun N. Statistical Report 2011: Thailand. Department of Medical Services, Ministry of Public Health in Thailand 2011:1-146.

[11] McKhann G, Drachman D, Folstein M, Katzman R, Price D, EM. S. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.

[12] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). R. R. Donnelly & Sons Company, Washington, DC 1994.

[13] Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008;4:38-48.

[14] Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from $A\beta_{1-42}$ are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95:6448-53.

[15] Mattson MP. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997;77:1081-132.

[16] Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-44.

[17] Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in *vivo* amyloid imaging load and cerebrospinal fluid $A\beta_{1-42}$ in humans. Ann Neurol 2006;59:512-9.

[18] Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, et al. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 2005;58:147-50.

[19] Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006;129:3042-50.

[20] Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998;338:506-11.

[21] Abdullah L, Luis C, Paris D, Mouzon B, Ait-Ghezala G, Keegan AP, et al. Serum Aβ levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort. Mol Med 2009;15:432-7.

[22] Kida E, Choi-Miura NH, Wisniewski KE. Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain. Brain Res 1995;685:211-6.

[23] McGeer PL, Kawamata T, Walker DG. Distribution of clusterin in Alzheimer brain tissue. Brain Res 1992;579:337-41.

[24] Wilson MR, Yerbury JJ, Poon S. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol Biosyst 2008;4:42-52.

[25] Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer's Aβ-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007;27:909-18.

[26] Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010;67:739-48.

[27] Kim DK, Seo MY, Lim SW, Kim S, Kim JW, Carroll BJ, et al. Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease. Neuropsychopharmacol 2001;25:84-90.

[28] Ujiie M, Dickstein DL, Jefferies WA. p97 as a biomarker for Alzheimer's disease. Front Biosci 2002;7:e42-7.

[29] Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 2007;61:120-9.

[30] Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer's disease in the United States (2010-2050) estimated using the 2010 Census. Neurology 2013;80:1778-83.

[31] Alzheimer's Association. Early-Onset Dementia: A National Challenge, a Future Crisis. Washington, D.C.: Alzheimer's Association 2006.

[32] Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007;29:125-32.

[33] Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 1998;55:809-15.

[34] Seshadri S, Drachman DA, Lippa CF. Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. Arch Neurol 1995;52:1074-9.

[35] Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997; 20:154-9.

[36] Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J Neurol Neurosurg Psychiatry 2003;74:857-62.

[37] Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 2007;69:1921-30.

[38] Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 1994;13:45-53.

[39] Jarrett JT, Berger EP, Lansbury PT, Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993;32:4693-7.

[40] Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, et al. β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA 1993;90:10836-40.

[41] Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000;33:95-130.

[42] Trojanowski JQ, Schuck T, Schmidt ML, Lee VM. Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem 1989;37:209-15.

[43] Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005;1739:198-210.

[44] Goldgaber D, Lerman ML, McBride WO, Saffiotti U, Gajdusek DC. Isolation, characterization, and chromosomal localization of human brain cDNA clones coding for the precursor of the amyloid of brain in Alzheimer's disease, Down's syndrome and aging. J Neural Transm 1987;24:23-8.

[45] Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-66.

[46] Lichtenthaler SF, Haass C. Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. J Clin Invest 2004;113:1384-7.

[47] Kojro E, Fahrenholz F. The non-amyloidogenic pathway: structure and function of alpha-secretases. Subcell Biochem 2005;38:105-27.

[48] De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 2000;113:1857-70.

[49] Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL, et al. Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome. Proc Natl Acad Sci 2010;107:6538-43.

[50] Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL. Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science 1990;248:492-5.

[51] Sisodia SS. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci USA 1992;89:6075-9.

[52] Roher AE, Palmer KC, Yurewicz EC, Ball MJ, Greenberg BD. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. JNeurochem 1993;61:1916-26.

[53] Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 1989;135:309-319.

[54] Gowing E, Roher AE, Woods AS, Cotter RJ, Chaney M, Little SP, et al. Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem 1994;269:10987-10990.

[55] Dickson DW. Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non-amyloid precursor to senile plaques? Am J Pathol 1997;151:7-11.

[56] Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord 2000;14:S47-53.

[57] Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid betapeptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996;3:16-32.

[58] Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-185.

[59] Selkoe DJ. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 1994;53:438-447.

[60] Strodel B, Lee JWL, Whittleston CS, Wales DJ. Transmembrane structures for alzheimer's A beta (1-42) oligomers. J. Am. Chem 2010;132:13300-13312.

[61] Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, et al. Structural conversion of neurotoxic amyloidbeta (1-42) oligomers to fibrils. Nature Struct Molec Biol 2010;17:561-568.

[62] Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the alzheimer's amyloid beta-peptide. Nature Rev Molec Cell Biol 2007;8:101-112.

[63] Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct Biol 2000;130:184-208.

[64] Gable CC. The Oligomer Structures and Toxicity, The Open Biology Journal, 2009;2:222-227.

[65] Rauk A. Why is the amyloid beta peptide of alzheimer's disease neurotoxic? Dalton Transactions 2009;10:1273-1282.

[66] Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease: The National Institute of Mental Health Genetics Initiative. Arch Neurol 1994;51:1198-1204.

[67] Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A. The Consortium to Establish a Registry for Alzheimer's disease (CERAD): Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 1995;45:461-466.

[68] Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). American Psychiatric Association: Arlington, VA 2000.

[69] Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.

[70] Foreman MD, Grabowski R. Diagnostic Dilemma: Cognitive Impairment in the Elderly. Gerontol Nursing 1992;18:5-12.

[71] Foreman MD, Fletcher K, Mion LC, Simon L. Assessing Cognitive Function. Geriatric Nursing 1996;17:228-233.

[72] Schneider LS. Assessing outcomes in Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15:S8-18.

[73] Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: a compreensive review. J Am Ger Soc 1992;40:922-935.

82

[74] Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994;51:888-95.

[75] Tierney MC, Fisher RH, Lewis AJ, Zorzitto ML, Snow WG, Reid DW, et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases. Neurology 1988;38:359-64.

[76] Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.

[77] Appel J, Potter E, Shen Q, Pantol G, Greig MT, Loewenstein D, et al. A comparative analysis of structural brain MRI in the diagnosis of Alzheimer's disease. Behav Neurol 2009;21:13-9.

[78] Tartaglia MC, Rosen HJ, Miller BL. Neuroimaging in dementia. Neurotherapeutics 2011;8:82-92.

[79] Silverman DH, Small GW, Phelps ME. Clinical value of neuroimaging in the diagnosis of dementia: Sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease. Clin Positron Imaging 1999;2:119-30.

[80] Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 2011;95:579-93.

[81] Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004;1:213-25.

[82] Mandelkow EM, Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol 1998;8:425-7.

[83] Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx 2004;1:226-234.

[84] Rosenberg PB, Lyketsos C. Mild cognitive impairment: searching for the prodrome of Alzheimer's disease. World Psychiatry 2008;7:72-8.

[85] Petersen RC. Clinical practice: Mild cognitive impairment. N Engl J Med 2011;364:2227-34.

[86] Molano J, Boeve B, Ferman T, Smith G, Parisi J, Dickson D, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain 2010;133:540-56.

[87] Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-88.

[88] Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 2006;67:441-5.

[89] Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 2004;63:115-21.

[90] Rountree SD, Waring SC, Chan WC, Lupo PJ, Darby EJ, Doody RS. Importance of subtle amnestic and non-amnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord 2007;24:476-82.

[91] Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46.

[92] Kelley BJ, Petersen RC. Alzheimer's disease and mild cognitive impairment. Neurol Clin 2007;25:577-609.

[93] Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397-405.

[94] Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13.

[95] Pirttila T, Kim KS, Mehta PD, Frey H, Wisniewski HM. Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls. J Neurol Sci 1994;127:90-95.

[96] Nakamura T, Shoji M, Harigaya Y, Watanabe M, Hosoda K, Cheung TT, et al. Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann Neurol 1994;36:903-911.

[97] Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.

[98] Diniz, BS, Pinto Junior JA, Forlenza OV. Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 2008;9:172-82.

[99] Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003;60:958-64.

[100] Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 1996;141:65-8.

[101] Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, et al. The beta APP$_{717}$ Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A$\beta_{42(43)}$. Neurology 1997;48:741-5.

[102] Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer's disease. Arch Neurol 2000;57:100-5.

[103] Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, et al. Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003;61:1185-90.

[104] Pomara N, Willoughby LM, Sidtis JJ, Mehta PD. Selective reductions in plasma Aβ1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry 2005;13:914-7.

[105] van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006;5:655-60.

[106] Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer's disease. Arch Neurol 2007;64:354-62.

[107] Locascio JJ, Fukumoto H, Yap L, Bottiglieri T, Growdon JH, Hyman BT, et al. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer's disease. Arch Neurol 2008;65:776-85.

[108] Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, et al. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging 2008;29:1-11.

86

[109] Schupf N, Patel B, Pang D, Zigman WB, Silverman W, Mehta PD, et al. Elevated plasma beta-amyloid peptide Aβ42 levels, incident dementia, and mortality in Down syndrome. Arch Neurol 2007;64:1007-13.

[110] Graff -Radford N. Analysis of plasma Aβ42 as a premorbid marker for late onset Alzheimer's disease. Neurobiol Aging 2004;25:354.

[111] Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R, et al. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 2004;63:828-31.

[112] Yerbury JJ, P oon S, Meehan S, Thompson B, Kumita JR, Dobson CM, Wilson MR: The extracellular chaperone clusterin infl uences amyloid formation and toxicity by interacting with prefi brillar structures. FASEB J 2007;21:2312-2322.

[113] Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, et al. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008;14:833-9.

[114] Caccamo AE, Scaltriti M, Caporali A, D'Arca D, Corti A, Corvetta D, et al. Ca^{2+} depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ 2005;12:101-4.

[115] Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol 2002;34:427-431.

[116] Yu JT, Tan L. The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy. Mol Neurobiol 2012;45:314-326.

[117] Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech 2000;50:305-15.

[118] Matsubara E, Frangione, B, Ghiso J. Characterization of apolipoprotein J Alzheimer's Aβ interaction. J Biol Chem 1995;270:7563-7.

[119] Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA 2011;305:1322-6.

[120] Gemma M, Mullan J, McEneny S, Todd M, Henry B, McGuinness P, et al. Apo J genotype and plasma levels in Alzheimer's disease 2013 May 1. [Epub ahead of print].

[121] Jefferies WA, Food MR, Gabathuler R, Rothenberger S, Yamada T, Yasuhara O, et al. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res 1996;712:122-6.

[122] Yamada T, Tsujioka Y, Taguchi J, Takahashi M, Tsuboi Y, Moroo I, et al. Melanotransferrin is produced by senile plaque-associated reactive microglia in Alzheimer's disease. Brain Res 1999;845:1-5.

[123] Kennard ML, Feldman H, Yamada T, Jefferies WA. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat Med 1996;2:1230-5.

[124] Liao PC, Yu L, Kuo CC, Lin C, Kuo YM. Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease. Proteomics-Clinical Applications 2007;1:506-512.

[125] Gollin PA, Kalaria RN, Eikelenboom P, Rozemuller A, Perry G. Alpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer's disease. Neuroreport 1992;3:201-3.

[126] Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994;269:15957-60.

[127] Sihlbom C, Davidsson P, Sjogren M, Wahlund LO, Nilsson CL. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochem Res 2008;33:1332-40.

[128] Strohmeyer R, Shen Y, Rogers J. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res Mol Brain Res 2000;81:7-18.

[129] Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P, Witt I, et al. Interleukin-6 and alpha-2-macroglobulin indicate an acutephase state in Alzheimer's disease cortices. FEBS Lett 1991;285:111-4.

[130] Cutler P, Akuffo EL, Bodnar WM, Briggs DM, Davis JB, Debouck CM, et al. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin. Appl 2008;2:2467-477.

[131] Liu HC, Hu CJ, Chang JG, Sung SM, Lee LS, Yuan RY, et al. Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement Geriatr Cogn Disord 2006;21:155-61.

[132] Koldamova RP, L.I, Lefterova MI, Lazo JS, Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 2001;40:3553-3560.

[133] Davidsson P, Sjogren M. Proteome studies of CSF in AD patients. Mech Ageing Dev 2006;127:133-7.

[134] Lopez MF, Mikulskis A, Kuzdzal S, Bennett DA, Kelly J, Golenko E, et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 2005;51:1946-54.

[135] German DC, Gurnani P, Nandi A, Garner HR, Fisher W, Diaz-Arrastia R, et al. Serum biomarkers for Alzheimer's disease: proteomic discovery. Biomed Pharmacother 2007;61:383-9.

[136] Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, Davies HA, et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 2007;64:366-70.

[137] Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 2000;49:171-86.

[138] Perry G, Friedman R, Shaw G, Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci U S A 1987;84:3033-6.

[139] Sultana R, Perluigi M, Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal 2006;8:2021-37.

[140] Thermo Scientific Pierce Electrophoresis Technical Handbook. Thermo Fisher Scientific 2010;2:1-44.

[141] Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004;4:3665-85.

[142] Westermeier R, Naven T. Proteomics in Practice: A Laboratory Manual of Proteome Analysis. Electrophoresis in Practice 2002;3:1-160.

[143] Grog A. Principle and Method of 2-D Electrophoresis. GE Healthcare 2004:1-162.

[144] Patton WF. Detection technologies in proteome analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2002;771:3-31.

[145] Westermeier R. A Guide to Methods and Applications of DNA and Protein Separations. Electrophoresis in Practice 2001;3:81-100

[146] Wiley J, Sons LTD, Mass Spectrometry: Principles and Applications 3rd Edition. Edmond de Hoffmann and Vincent Stroobant 2007;3:1-489.

[147] Greiner M. Two-graph receiver operating characteristic (TG-ROC): Update version supports optimisation of cut-off values that minimise overall misclassification costs. J Immunol Methods 1996;191:93-4.

[148] Mehta PD. Amyloid beta protein as a marker or risk factor of Alzheimer's disease. Curr Alzheimer Res 2007;4:359-63.

[149] Zetterberg H, Blennow K, Hanse E. Amyloid beta and APP as biomarkers for Alzheimer's disease. Exp Gerontol 2010;45:23-9.

[150] Irizarry MC, Yao Y, Hyman BT, Growdon JH, Pratico D. Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Neurodegener Dis 2007;4:403-5.

[151] Bons JA, Wodzig WK, van Dieijen-Visser MP. Protein profiling as a diagnostic tool in clinical chemistry: a review. Clin Chem Lab Med 2005;43:1281-90.

[152] Chiu MJ, Yang SY, Chen TF, Chieh JJ, Huang TZ, Yip PK, et al. New assay for old markers plasma beta amyloid of mild cognitive impairment and Alzheimer's disease. Curr Alzheimer Res 2012;9:1142-8.

[153] Patel S, Shah RJ, Coleman P, Sabbagh M. Potential peripheral biomarkers for the diagnosis of Alzheimer's disease. Int J Alzheimers Dis 2011:572495.

91

[154] Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007;28:977-86.

[155] Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm 2012;119:843-50.

[156] Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, et al. Relative abundance of Alzheimer $A\beta$ peptide variants in Alzheimer's disease and normal aging. Proc Natl Acad Sci USA 1994;91:8378-82.

[157] Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996;271:32916-22.

[158] Kuo YM, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA, Woods AS, et al. High levels of circulating $A\beta_{42}$ are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 1999;257:787-91.

[159] Koudinov A, Matsubara E, Frangione B, Ghiso J. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 1994;205:1164-71.

[160] Kuo YM, Kokjohn TA, Watson MD, Woods AS, Cotter RJ, Sue LI, et al. Elevated $A\beta_{42}$ in skeletal muscle of Alzheimer's disease patients suggests peripheral alterations of $A\beta$-APP metabolism. Am J Pathol 2000;156:797-805.

[161] Oh ES, Troncoso JC, Fangmark Tucker SM. Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. Neuromolecular Med 2008;10:195-207.

92

[162] Selkoe DJ, Podlisny MB, Joachim CL, Vickers EA, Lee G, Fritz LC, et al. Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc Natl Acad Sci USA 1988;85:7341-5.

[163] Thambisetty M, An Y, Kinsey A, Koka D, Saleem M, Guntert A, et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 2012;59:212-7.

[164] Mullan GM, McEneny J, Fuchs M, McMaster C, Todd S, McGuinness B, et al. Plasma clusterin levels and the rs11136000 genotype in individuals with mild cognitive impairment and Alzheimer's disease. Curr Alzheimer Res 2013;10:973-8.

[165] Matsubara E, Soto C, Governale S, Frangione B, Ghiso J. Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem J 1996;316:671-9.

[166] Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 2010;31:357-67.

[167] Rothenberger S, Food MR, Gabathuler R, Kennard ML, Yamada T, Yasuhara O, et al. Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium. Brain Res 1996;712:117-21.

[168] Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2014:CD008782.

[169] Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, et al. Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models. Biochem Biophys Res Commun 2009;385:193-7.

[170] The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". Neurobiol Aging 1998;19:109-16.

[171] Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, Smith C, et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004;4:244-56.

[172] Choi, J, et al., Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 2002;293:1566-70.

[173] Song F, Poljak A, Smythe GA, Sachdev P. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev 2009;6:69-80.

[174] Lista S, Faltraco F, Prvulovic D, Hampel H. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol 2013;101:1-17.

94